OriGene Technologies Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OriGene Technologies Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10873
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OriGene Technologies Inc (OriGene) is a research tool company that develops cDNA. The company creates commercial collection of full-length human cDNAs in expression vector. It develops, manufactures and markets genome research and diagnostic products. OriGene provides products such as qPCR reagents, transfection reagent, precisionshuttling kits, cDNA clones, HuSH shRNA, plasmid purification, siRNA, miRNA, proteins antibodies, IHC products, assays and human tissues, among others. The company provides services such asd gene synthesis, custom shRNA, custom cloning, custom protein service, antibody service, assay development and stable cell line development. It offers research in the areas of cancer biomarker research, pathology IHC, stem cell research, ion channels, protein kinase, and others. The company provides products and services to pharmaceutical and biotechnology companies and academic research institutes. OriGene is headquartered in Rockville, Maryland, the US.

OriGene Technologies Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OriGene Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OriGene Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 8
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Strategic Diagnostics Completes Sale Of Life Science Business Assets To OriGene For US$16 Million 10
Venture Financing 12
OriGene Technologies Raises USD6.4 Million in Venture Financing 12
OriGene Technologies Raises Funds in Financing Round 13
OriGene Technologies Raises USD17 Million in Venture Financing 14
OriGene Technologies Raises USD0.2 Million in Venture Financing 15
OriGene Technologies Raises US$21 Million In Series C Financing 16
Origene Technologies Raises US$15 Million In Venture Financing 17
Partnerships 18
OriGene Technologies Enters into Contract with National Cancer Institute 18
Entia Biosciences Enters Into Co-Development Agreement With Biocheck 19
Licensing Agreements 20
Dako Enters into Licensing Agreement with OriGene Technologies 20
Asset Transactions 21
Strategic Diagnostics Completes Sale Of Life Science Business Assets To OriGene For US$16 Million 21
Romer Labs Completes Acquisition Of Food Safety And GMO Business Of Strategic Diagnostics For US$13.5 Million 23
Acquisition 24
OriGene Technologies Acquires Acris Antibodies 24
OriGene Technologies Inc – Key Competitors 25
OriGene Technologies Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Key Facts 2
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OriGene Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OriGene Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 8
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Strategic Diagnostics Completes Sale Of Life Science Business Assets To OriGene For US$16 Million 10
OriGene Technologies Raises USD6.4 Million in Venture Financing 12
OriGene Technologies Raises Funds in Financing Round 13
OriGene Technologies Raises USD17 Million in Venture Financing 14
OriGene Technologies Raises USD0.2 Million in Venture Financing 15
OriGene Technologies Raises US$21 Million In Series C Financing 16
Origene Technologies Raises US$15 Million In Venture Financing 17
OriGene Technologies Enters into Contract with National Cancer Institute 18
Entia Biosciences Enters Into Co-Development Agreement With Biocheck 19
Dako Enters into Licensing Agreement with OriGene Technologies 20
Strategic Diagnostics Completes Sale Of Life Science Business Assets To OriGene For US$16 Million 21
Romer Labs Completes Acquisition Of Food Safety And GMO Business Of Strategic Diagnostics For US$13.5 Million 23
OriGene Technologies Acquires Acris Antibodies 24
OriGene Technologies Inc, Key Competitors 25
OriGene Technologies Inc, Subsidiaries 26

List of Figures
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OriGene Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OriGene Technologies Inc, Medical Devices Deals, 2012 to YTD 2018 8

★海外企業調査レポート[OriGene Technologies Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Movado Group, Inc. (MOV):企業の財務・戦略的SWOT分析
    Movado Group, Inc. (MOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Accenture plc:企業の戦略・SWOT・財務情報
    Accenture plc - Strategy, SWOT and Corporate Finance Report Summary Accenture plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Graftys SA:製品パイプライン分析
    Summary Graftys SA (Graftys) is a medical device company that focuses on the development, manufacture and commercialization of synthetic bioactive orthopedic biomaterials. It provides a wide range of synthetic and bioresorbable bone graft substitutes and other cement products. The company’s products …
  • Drugs for Neglected Diseases initiative:製薬・医療:M&Aディール及び事業提携情報
    Summary Drugs for Neglected Diseases initiative (DNDi) is a non-profit drug research and development (R&D) organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis (H …
  • First Pacific Co Ltd (142):企業の財務・戦略的SWOT分析
    First Pacific Co Ltd (142) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Savannah Resources Plc:企業のM&A・事業提携・投資動向
    Savannah Resources Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Savannah Resources Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Domainex Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Domainex Ltd (Domainex) is a drug discovery service company that offers drug discovery programmes against a wide range of drug targets. The company provides services such as molecular biology / cdh, protein expression, assays, fragment screening, virtual screening, computational chemistry, m …
  • Metropolitan Bank and Trust Company:企業の戦略・SWOT・財務情報
    Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report Summary Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Applied Industrial Technologies Inc (AIT):石油・ガス:M&Aディール及び事業提携情報
    Summary Applied Industrial Technologies Inc. (Applied Industrial) is a distributor of industrial products and services to MRO and OEM customers. The company also provides engineering, design and systems integration services for industrial and fluid power applications, besides tailored mechanical, fa …
  • TiVo Corp.:企業の戦略・SWOT・財務分析
    TiVo Corp. - Strategy, SWOT and Corporate Finance Report Summary TiVo Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • SmarTone Mobile Communications Ltd:企業の戦略的SWOT分析
    SmarTone Mobile Communications Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Quickstep Holdings Limited:企業の戦略・SWOT・財務情報
    Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Rafael Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rafael Pharmaceuticals Inc (Rafael Pharmaceuticals), formerly Cornerstone Pharmaceuticals Inc, is a clinical-stage, metabolic oncology therapeutics company, which focuses to develop and commercialize cancer metabolism based drugs. The company’s lead drug candidate CPI-613 is designed to targ …
  • Harvard Bioscience Inc (HBIO):企業の財務・戦略的SWOT分析
    Harvard Bioscience Inc (HBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Goodwin Biotechnology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Goodwin Biotechnology Inc (GBI), a subsidiary of Wallace Pharmaceuticals Pvt Ltd is a healthcare company that develops and manufactures vaccines, monoclonal antibodies, recombinant proteins and bioconjugates. The company offers cell culture, purification, bioconjugation, biosimilars, aseptic …
  • Aevi Genomic Medicine Inc (GNMX)-製薬・医療分野:企業M&A・提携分析
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company’s pipeline products include AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamaterg …
  • Milagen Inc:企業の製品パイプライン分析
    Summary Milagen Inc (Milagen) is a medical device company. It provides diagnostic products. The company generates antibody reagents against the human proteome. It discovers, develops and markets non invasive immunodiagnostic products for monitoring, surveillance and detection of cancers. Milagen off …
  • Biosceptre International Ltd-医療機器分野:企業M&A・提携分析
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Biosceptre’s diagnostic products are …
  • Key Energy Services Inc (KEGXD):企業の財務・戦略的SWOT分析
    Key Energy Services Inc (KEGXD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Alsea SAB de CV:企業の戦略・SWOT・財務情報
    Alsea SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Alsea SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆